137,632 research outputs found
Bilateral microform cleft lip
No full textMicroform cleft lip (MCL), also called congenital healed cleft lip or cleft lip "frustré", is a rare congenital anomaly. MCL has been described as having the characteristic appearance of a typical cleft lip which has been corrected in utero. We present a girl with bilateral microform cleft lip associated with a preauricular sinus and bilateral camptodactyly.peer-reviewe
A new bottle design to correct mechanical defect during feeding in cleft lip and palate babies
No full textThis thesis was submitted for the degree of Doctor of Philosophy and awarded by Brunel UniversityBabies with cleft lip and palate which is a common craniofacial deformity suffer from feeding problem which interfere with their growth and development and render the subsequent corrective surgery and also endure their daily suffering during the feeding time. This thesis reports the design of a new bottle feed to overcome this problem. Also a clinical study was preformed to study the patterns of baby feed in cleft lip and palate babies to support the use of the bottle feeding for this group of babies
Dentofacial Characteristics Of Malay Patients With Repaired Cleft Lip And Palate In Kelantan [RD524. B138 2005 f rb].
No full textRekahan bibir dan lelangit (CLP) adalah suatu kecacatan kongenital muka yang sering ditemui. Pesakit CLP mengalami masalah makan, bernafas, infeksi telinga tengah, masalah psikososial dan lain-lain. Rawatannya memerlukan penglibatan pelbagai disiplin yang bermula dari hari pertama dilahirkan dan berterusan hingga peringkat umur 20 ke 21 tahun.
Cleft lip and palate (CLP) is the most common congenital facial defect. Patients with CLP suffer from feeding, breathing, middle ear infections as well as psychosocial and other problems. The treatment requires interventions from multiple disciplines which start from the first day of life and continue up to the age of 20 to 21 years
Combination therapy with HDACi enhances the cytotoxicity of Fuc-Lip-sorafenib.
No full text(A) AFP-L3 expressing HepG2, and JHH7 cells, and AFP-L3 non-expressing JHH6 cells were treated for 2 h with F0-Lip-sorafenib or F50-Lip-sorafenib. The cells were then, washed, incubated for 48 h, and cell viability was measured by BrdU assay. The percentage of viable cells is shown compared with untreated cells. (B) HCC cells were treated with F0-Lip-sorafenib or F50-Lip-sorafenib (5 μM) for 2 h with or without SAHA (1 μM) and, then washed and incubated for 48 h. Cell viability was measured by BrdU assay. Experiments were carried out in triplicate and repeated three times. NT: no treatment. * P < 0.05.</p
Complementing surgical with biomedical and engineering methods to evolve lip and nose reconstruction
No full textFacial integrity and self-perception are intimately related to each other. A facial defect therefore affects a patient in his physical and psychosocial health as well. Every reconstructive method exhibit certain imperfections or burden for the patient, which motivates the surgeon’s to strive for improvements. While many imperfections can be improved by refinements of the surgical techniques, some aspects might be not solvable by surgical principles alone. At that stage, biomedical and engineering methods should be considered to complement the surgical treatment for further improvements.
We developed and explored a variety of biomedical and engineering methods to overcome shortcomings of current lip-nose reconstruction techniques.
The unknown shape of a missing nose was computed from a morphable face model that comprise the facial shape information of 200 healthy individuals. It led to a more natural shape planning than by hand carving. A biocompatible facial prosthesis was then made out of polyamide using computer assisted design and manufacturing. Alternatively to facial prosthesis large facial defects can be covered by means of tissue transfer from a distant body site performing a microsurgical vascular anastomosis. In this area, the importance to develop and use monitoring devices and pharmaceutical drugs for anastomosis patency remained unclear. We assessed therefore the current practice for microsurgical head and neck tissue transfer in clinics of Germany, Switzerland and Austria. There was a high variability with equal success rate, technical monitoring devices and pharmaceutical drugs seemed to have a negligible effect on the success rate, while the surgical anastomosis having the main effect. To repair small naso-labial defects of inborn cleft lips, the use of the adjoining tissue is sufficient. However, since both lip parts contain a labial artery of normal thickness they could be as well unified by a microsurgical anastomosis, however its biological rational needed exploration. We measured the lip artery blood flow and nose-lip microcirculation in cleft lip patients before and after surgical repair and in normal using laser Doppler flowmetry and white light tissue spectrometry. We found no circulation deficit in cleft patients and therefore no need to strive for a surgical anastomosis. Nonetheless, since blood flow is a precondition for growth and development, visible vessels in the surgical field should be preserved best possible. We therefore studied the intraoperative vascular anatomy for constant vascular findings. A perforating artery of the Musculus transversus nasalis was identified at the nasal ala on the cleft side, which could be constrantly preserved after it became aware.
The aim to refine a surgical treatment should not exclusively focus on the surgical technique but need also consider the burden of the entire treatment plan. More than 95% of the European cleft surgery centers use 2 to 4 surgeries to close the cleft of the lip, alveolus, hard, and soft palate –considering that this optimizes growth of the cleft maxilla. But facing the burden of repetitive surgeries for patient and family, Dr. Honigmann introduced in Basel 1991 the cleft repair in one single operation at “one-stage”. We were now able to assess the long-term growth effect of this procedure, which showed the same growth results as compared to multi-stage procedure. But when compared to normal, 20% to 45% of the cleft patients still showed a growth deficit that would require surgery to normalize the dental relation and facial profile. The orthognathic surgery rate in cleft patients from the literature ranges also widely from about 20% to 45%, whatever surgical technique and treatment plan is applied. It is therefore doubtful that by surgical means alone the growth deficit can be avoided. This prompted us to assess the in-vitro and in-vivo osteogenic capacity of stem cells from the umbilical cord Wharton’s jelly (WJMSC) under fully defined conditions allowing for clinical translation. Due to prenatal ultrasound the cleft lip malformation is frequently known before birth, and the umbilical cord could thus serve as an autologous stem cell donor site without any harvesting morbidity. Both, Osteogenically differentiated WJMSCs and WJ tissue biopsies produced a mineralized extracellular matrix. The expression of genes of osteoblastic lineage increased significantly after 3 weeks of osteodifferentiation. Although the WJMSCs formed in-vitro a dense collageneous matrix with signs of osteoblastic differentiation, no mature bone tissue was found after 8 weeks after subcutaneous implantation in immunoincompetent mice. Further in-vivo tests are therefore necessary applying more favorable bone forming conditions by using ostegenic predifferentiated cells and implantation into a bone defect.
In sum, biomedical and engineering methods have been applied to solve surgical problems or to establish new therapeutic strategies where conventional lip and nose reconstruction methods reach their limits. This has been demonstrated at different lip and nose reconstructive levels reaching from prosthetics, over microsurgery, to stem cell tissue engineering
Acetylated-p53 by HDACi up-regulates FUT8 expression and incorporation of Fuc-Lip-Cy5.5 into cells.
No full text(A) HepG2,JHH7 and JHH6 cells were exposed to SAHA for 6 h and then the expression levels of p53, Acetylated-p53 (Ac-p53), and FUT8 proteins were analyzed by western blot. (B) Efficacies of incorporation of Fuc-Lip-Cy5.5 into cells. Cells were treated with SAHA (0, 1, 5 μM) for 6 h, then incubated with Fuc-Lip-Cy5.5 for 30 min, and subsequently incorporation of Cy5.5 was analyzed by flow cytometry. The percentages of Cy5.5-positive cells are shown. F0, F0-Lip-Cy5.5: F25, F25-Lip-Cy5.5: F50, F50-Lip-Cy5.5. Experiments were carried out in triplicate and repeated twice.</p
Going Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Three-dimensional cephalometric evaluation of maxillary growth following in utero repair of cleft lip and alveolar-like defects in the mid-gestational sheep model
No full textObjective: To evaluate maxillary growth following in utero repair of surgically created cleft lip and alveolar (CLA)-like defects by means of three-dimensional (3D) computer tomographic (CT) cephalometric analysis in the mid-gestational sheep model. Methods: In 12 sheep fetuses a unilateral CLA-like defect was created in utero (untreated control group: 4 fetuses). Four different bone grafts were used for the alveolar defect closure. After euthanasia, CT scans of the skulls of the fetuses, 3D re-constructions, and a 3D-CT cephalometric analysis were performed. Results: The comparisons between the operated and nonoperated skull sides as well as of the maxillary asymmetry among the experimental groups revealed no statistically significant differences of the 12 variables used. Conclusions: None of the surgical approaches used for the in utero correction of CLA-like defects seem to affect significantly postsurgical maxillary growth; however, when bone graft healing takes place, a tendency for almost normal maxillary growth can be observed. Copyright (c) 2006 S. Karger AG, Basel
p53 and FUT8 regulate the introduction of Fuc-Lip-Cy5.5 into HCC cells.
No full text(A) Expression levels of p53 and FUT8 in HCC cells were examined by western blot. (B) Quantification of AFP-L3 values. (C) Determination of the introduction of Fuc-Lip-Cy5.5 into HCC cells. After siRNA transfection, HepG2 and JHH7 cells were exposed to 1 μM SAHA for 6 h, then treated with F50-Lip-Cy5.5 for 30 min and analyzed by flow cytometry. One siRNA was used for p53 (si-p53) and two were used for FUT8 (si-FUT8-1 and si-FUT8-2). Experiments were carried out in triplicate and repeated at least three times.</p
Combination of HDACi and Fuc-Lip-sorafenib augments tumor suppression <i>in vivo</i>.
No full text(A) Treatment schedule for the HepG2 xenograft mouse model. F0-Lip-sorafenib (1 mg/kg), or F50-Lip-sorafenib solution (1 mg/kg) was administered via tail vein injection twice a week for seven weeks. SAHA (1 mg/kg) was administered daily intraperitoneally. (B) Tumor volumes for each treatment group. At every treatment schedule, tumor volumes were measured according to the formula = length x width2 / 2. (C) Tumor tissue was prepared on day 45 after the start of treatment. HE and TUNEL staining in HepG2 tumors are shown. Veh: Vehicle. *P P < 0.01.</p
- …
